Kornimate/medical-research-clean huggingface dataset:
endovascular treatment of atherosclerotic lesions in the sfa using the sinus-superflex-635 stent

Conditions: Atherosclerotic Heart Disease

Summary: in this prospective study, a newly developed self-expanding nitinol stent is evaluated for the treatment of atherosclerotic lesions in the superficial femoral artery and proximal popliteal artery.


Eligibility criteria:
inclusion criteria: * patient must sign informed consent prior to the index-procedure * patient must be older than 18 years * patient must be compliant with follow-up dates at 1 month and 12 months * patients with intermittent claudication (rutherford 2-3) and critical limb ischemia (rutherford 4-5) * target lesion is located in the superficial femoral artery (minimal 1 cm from origin of sfa and minimal 1 cm above the edge of the patella) * reference vessel diameter ≥4.5 and ≤6.5 mm (visual estimate) * patients with a tasc a, b or c lesion * diameter stenosis of target lesion \>50% or chronic occlusions * inflow arteries are free of hemodynamically significant obstruction (i.e. ≥50%) * the popliteal artery (outflow) is free of hemodynamically significant obstruction (i.e. ≥50%) * at least 1 patent below-the-knee vessel (anterior tibial artery, posterior tibial artery or peroneal artery) till the ankle confirmed by baseline angiography exclusion criteria: * patients with rutherford 1 and 6 * patiens with serum creatinine \> 2.0 mg/dl or renal dialysis * patient takes esomeprazole or omeprazole * patient is pregnant * patient suffers from acute limb ischemia defined as any sudden decrease in limb perfusion causing a potential threat to limb viability * target lesion cannot be crossed with a guidewire * target lesion is located in the popliteal artery * patients with a nickel-titanium allergy * patients with an aneurysm in the superficial femoral artery and popliteal artery * patients with a tasc d lesion * patients with a life expectancy \<1 year * patients with scheduled elective non-vascular procedures within 3 months after index-procedure, vascular procedures are allowed within 3 months after index-procedure if it is guaranteed that acetylic salicylic acid and clopidogrel intake is not interrupted * patients with previous bypass surgery in the sfa * patients with intolerance to antithrombotic medication (acetylic salicylic acid, clopidogrel, ticlopidine, glycoprotein iib/iiia inhibitors, direct thrombin inhibitors, etc) * patient has not been premedicated with acetylic salicylic acid (at least 80 mg/day) 2 hours before the index-procedure * patient has not been premedicated with clopidogrel (600 mg/day) 2 hours before the index-procedure

Keywords: peripheral artery disease sfa ppa self-expandable nitinol stent endovascular stenosis primary pantency
study to test software algorithm for insulin therapy and new glucose sensor

Conditions: Diabetes

Summary: to investigate the performance of a software-algorithm based insulin therapy to control blood glucose in type 1 diabetic patients.


Eligibility criteria:
inclusion criteria: * male or female aged 18 to 75 years (both inclusive) * informed consent obtained after being advised of the nature of the study * the subject has type 1 diabetes (as defined by who) for at least 24 months * the subject's hba1c \<= 10% * body mass index (bmi) \<= 35 kg/m2 * the subject is treated with continuous subcutaneous insulin infusion for at least 3 month exclusion criteria: * subject is actively enrolled in another clinical trial or took part in a study within 30 days * experienced recurrent severe hypoglycaemic unawareness * total daily insulin dose \>= 1.4 iu/kg * subject is using a medication that significantly impacts glucose metabolism (oral or topical steroids) except if stable for at least the last three months and expected to remain stable for the study duration * allergy against insulin lispro * a history of drug or alcohol dependence * any other significant concomitant disease such as endocrine, cardiac, neurological, malignant, other pancreatic disease or uncontrolled hypertension as judged by the investigator * uncontrolled hypertension with resting blood pressure over 140/90 mmhg * patient is pregnant, or breast feeding during the period of the study * patient donated blood in the last 3 months
poem for spastic esophageal disorders

Conditions: Esophageal Achalasia

Summary: this study evaluates the efficacy and safety of the per-oral endoscopic myotomy (poem) technique for lower esophageal sphincter myotomy in patients suffering from spastic esophageal disorders such as achalasia at a canadian institution. the investigators hypothesize that poem is a safe and effective technique for the surgical management of such disorders at our institution.

standard surgical care for spastic esophageal disorders such as achalasia includes a procedure called heller myotomy. the treatment in our study, called endoscopic myotomy (also known as peroral endoscopic myotomy - poem) is different from standard surgery (heller myotomy) because it is less invasive, is less likely to cause reflux, and usually requires shorter operative times with less loss of blood during the surgery. although poem has been adopted worldwide and has proven to be successful, the experience in canada is very limited to date.

Eligibility criteria:
inclusion criteria: * symptomatic achalasia or similar spastic esophageal disorder and pre-op barium swallow, manometry, and esophagogastroduodenoscopy being consistent with the diagnosis * ability to undergo general anesthesia * age \> 18 yrs and \< 85 yrs. of age * ability to give informed consent * candidate for elective heller myotomy exclusion criteria: * contraindications for esophagogastroduodenoscopy * contraindications for elective heller myotomy * bmi \> 45 * currently pregnant * refusing to participate in the study or without informed consent * concomitant participation in other clinical trial

Keywords: poem minimally invasive surgery achalasia spastic esophageal disorders
olive oil phonophoresis and chronic low back

Conditions: Low Back Pain

Summary: this study is intended to evaluate the effect of olive oil phonophoresis on chronic law back pain in female athletes.

this study will enroll 60 female patients suffering from chronic low back pain. the study will run in single blind mode that only patients will kept unaware of treatment. the duration of treatment is 10 days. patients will be assigned randomly to olive oil or placebo group. every day, they will take phonophoresis on lower back using phonophoresis gel as placebo or olive oil as treatment for 10 day. the questionnaires will be filled in baseline visit and day 10. any side effect of drugs or technique will be recorded

Eligibility criteria:
inclusion criteria: * young female athletes suffering from low back pain for more than three months exclusion criteria: * underlying systematic or visceral disease * specific conditions such as neoplasm and fractures, spondylolisthesis * previous low back surgery * pregnancy

Keywords: low back pain topical olive oil phonophoresis
to investigate the safety, tolerability, pharmacokinetics and the relative bioavailability of bi 1026706

Conditions: Healthy

Summary: to investigate the safety, tolerability, pharmacokinetics and the relative bioavailability of bi 1026706


Eligibility criteria:
inclusion criteria: 1. healthy male subjects exclusion criteria: 1. any relevant deviation from healthy conditions
dercos ds dandruff treatment observational study 2022

Conditions: Dandruff

Summary: the aim of this study is to evaluate the satisfaction / tolerance / cosmeticity of dercos ds


Eligibility criteria:
inclusion criteria: * patients with dandruff or seborrheic dermatitis * all hair types * all ethnicities (asian, caucasian, afro-american, african, hispanic) * including patients with specific occlusion habits (for instance veil use at least 8 hours per day, hat use) * patients willing to provide written informed consent exclusion criteria: * under 12 years old * pregnancy, breast feeding, childbearing potential without adequate contraception, or irregular menstrual cycles. * history of allergy, anaphylaxis or hypersensitivity to any of the ingredients of shampoo any of the ingredients of dercos anti-dandruff normal to oily hair shampoo * history of allergic contact dermatitis secondary to shampoo, conditioner, mask, and/or leave-in. * has any clinical manifestations in the treatment(s) or other disorders that, in the opinion of the investigator, may affect the evaluations or results of the study products.- inability to stay the study period (56 days +-5 days) without performing any hair/scalp procedure, including coloring, straightening and cutting. * inability to attend all study visits and follow treatment regimen

Keywords: dandruff treatment satisfaction
perception of needs of patients with chronic intestinal failure and their practitioners: a qualitative study

Conditions: Chronic Intestinal Failure; Small Intestine Disease

Summary: the sbs needs study is a qualitative transversal study aiming to describe and understand the needs and knowledge of patients with chronic intestinal failure as well as the representations of their practitioners chronic intestinal failure (cif) is the long-lasting reduction of gut function, below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth. cif is the rarest organ failure. home parenteral nutrition (hpn) is the primary treatment for cif. semi-structured interviews will be conducted with patients in two nutrition unit and specialized in the small bowel diseases in two french region. 20 situations will be included. after analysing the data of the individual interviews, focus groups will be conducted with health professionals from an accredited home parenteral nutrition department.


Eligibility criteria:
inclusion criteria: * men and women aged 18 and over * with chronic intestinal failure (cif) : "reduction of the intestinal functional mass below the minimum mass sufficient to ensure the absorption of nutrients to maintain nutritional status" * medical follow-up in one of the two nutrition departments of the study * informed consent stating that the subject understood the purpose and methodology of the study and agrees to participate in the study. exclusion criteria: * persons with proven and significant cognitive impairment preventing the completion of semi-structured interviews * person who does not speak french easily * generally, any person unlikely to cooperate in the study * adults under guardianship
efficacy and safety of gynostemma pentaphyllum(dungkulcha) extract on alleviation of chronic stress-induced strain

Conditions: Chronic Stress-Induced Strain

Summary: the investigators performed a 8-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of gynostemma pentaphyllum(dungkulcha) on alleviation of chronic stress-induced strain. the investigators measured decrement of body fat parameters, state\&trait version of stai, beck anxiety inventory(bai), hamilton anxiety inventory(ham-a), and monitored their blood pressure.


Eligibility criteria:
inclusion criteria: • age 20-65 years with chronic stress( s-stai score 40\~60) exclusion criteria: * excessive physically chronic fatigue * subjects taking antidepressants, anxiolytics, hypnotics within the last 2 months prior to the study * cardiovascular disease * allergic or hypersensitive to any of the ingredients in the test products * history of reaction to any of the test products or of gastrointestinal diseases such as crohn's disease or gastrointestinal surgery * participation in any other clinical trials within past 2 months * renal disease * abnormal hepatic function * laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * history of alcohol or substance abuse * pregnancy or lacting women etc.
use of the lru pillow in the acute setting following total knee arthroplasty

Conditions: Osteoarthritis

Summary: the null hypothesis is that there is no significant change in range of motion (rom), pain, or function for a group of patients following total knee arthroplasty (tka) who use the lru pillow as compared to a control group of total knee arthroplasty patients who do not use the pillow.

1. study design will be a pretest-posttest control group design . enrollment would be random assignment of 20 patients to a control group vs 20 patients to a treatment group for patients with the diagnosis of osteoarthritis (oa) of the knee admitted for primary total knee arthroplasty. for specifics of patient assignment, please see below under recruitment procedures. 2. unpaired t-tests will be used to determine differences between mean scores for the dependent variables (pain, range of motion, functional mobility). analysis of covariance will be run to quantify the effect of the co-variates of age, gender, body mass index (bmi), and contralateral previous tka. confidence intervals will be set at 95%.

Eligibility criteria:
inclusion criteria: * primary total knee arthroplasty patients with primary diagnosis of osteoarthritis. exclusion criteria: * bilateral total knee arthroplasties * revision total knee arthroplasties * unexpected decline in medical or mental status * subjects will range from 30 years of age to 80 years of age * primary diagnosis of rheumatoid arthritis

Keywords: lru total knee arthroplasty total knee replacement acute rehabilitation total knee total knee range of motion total knee acute care outcomes
phase 2 to assess efficacy and safety in ar882 alone or in combination with allopurinol in patients with tophaceous gout

Conditions: Gout; Arthritis, Gouty; Hyperuricemia; Gout Chronic

Summary: this study will assess the serum urate lowering effect, tophi reduction, and safety of ar882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.


Eligibility criteria:
inclusion criteria: * history of gout * at least 1 measurable tophus on the hands/wrists and/or feet/ankles ≥ 5 mm and ≤ 30 mm in the longest diameter. * patients who are not on approved ult must have sua \> 7 mg/dl * patients who are on medically appropriate ult must have sua \> 6 mg/dl * estimated glomerular filtration rate (egfr) ≥ 45 ml/min/1.73m2 exclusion criteria: * malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin * pregnant or breastfeeding * history of kidney stones
clinical study of antiviral and aspirin treatment in liver cancer after radical surgery

Conditions: Hepatocellular Carcinoma; Recurrence

Summary: evaluation the treatment outcome of antiviral and aspirin treatment in liver cancer after radical surgery.

the investigators conduct this clinical trial to evaluate the treatment outcome of antiviral and aspirin treatment in liver cancer after radical surgery.the primary outcome is overall survival and objective response rate.

Eligibility criteria:
inclusion criteria: * hepatocellular carcinoma confirmed with pathology or identified with radiological images with typical features * age ≥ 18 years and ≤ 75 years * at least one tumor nodule with one uni-dimension of ≥ 2 cm * child-pugh class a or b * hbv-dna\>10\^4 * total bilirubin ≤ 1.5 x upper limit of normal * alt and ast ≤ 2.0 x the upper limit of normal * pt-inr\<2.3,ptt \< 1.5 x upper limit of normal * serum creatinine ≤ 1.5x upper limit of normal * peripheral white blood cell count of or more than 3×10(9)/l * peripheral platelet of or more than 50×10(9)/l * expected survival time not less than 3 months * ecog score 0-2 exclusion criteria: * tumor thrombi in main branch of portal vein * tumor involvement more than 70% of whole liver * with extrahepatic metastasis * prior systemic chemotherapy or chemoembolization * congestive heart failure \> nyha class 2 * history of hiv infection * active clinically serious infections (\> 2 nci-ctc version 3.0) * recurrence of hcc after liver transplantation * pregnant or breast-feeding * substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in this study * known or suspected allergy to any agent given in association with this trial * patients unable to swallow oral medication * inclined to thrombosis * inclined to hemorrhage or active hemorrhage with 1 month

Keywords: hepatocellular carcinoma aspirin antiviral treatment recurrence free survival radical therapy
study of time-restricted eating (tre) to clinical pregnancy rate in pcos women with glucose metabolism disorder via ivf/icsi

Conditions: PCOS; Glucose Metabolism Disorder; IVF Outcome

Summary: investigate the effect and mechanism of time-restricted eating (tre) on the clinical pregnancy rate in women with pcos and glucose metabolism disorder via ivf/ icsi.

in this multicenter randomized controlled study, investigators plan to recruit 254 patients, aged 20-38, with pcos and glucose metabolism disorder. pcos diagnostic criteria based on rotterdam 2003 criteria, glucose metabolism disorder are diagnosed by 1998 who diagnostic criteria, with hba1c≤7%. participants selected are overweight or obese (24kg/m2 ≤ bmi ≤40kg/m2), and are planned to start the 1st/ 2nd cycle of ivf/ icsi. investigators divide these patients randomly into 2 groups (each group with 127 patients): metformin only group (control group) and tre with metformin group. every participant receives the specific treatment according to the group for at least 6 weeks. during the intervention period, follow-ups, blood chemistry tests and examinations are recorded every 2 weeks. after the intervention period, ivf/ icsi is carried out. gnrh-agonist- or/and hcg-triggered is used for ovarian stimulation. ovum retrieval will be carried out 34-36h after ovarian stimulation. blood hcg is tested after 12-14 days after embryonic transfer. for patients with positive hcg, clinical pregnancy is confirmed by observing gestational sac via transvaginal ultrasound after 4-5 weeks. investigators compare the terminal pregnancy-related result and metabolic changes between 2 groups to determine the effect and the possible mechanisms of tre on ivf/ icsi clinical pregnancy rate of pcos with glucose metabolism disorder patients.

Eligibility criteria:
inclusion criteria: 1. diagnosed with pcos based on rotterdam 2003 (all 3 criteria should be fulfilled); 2. diagnosed with glucose metabolism disorder (igt, ifg, igt with ifg, t2dm) and hba1c less than or equal to 7%; 3. age 20-38; 4. overweight or obese (24kg/m2 ≤ bmi ≤40kg/m2); 5. indication for ivf/ icsi (repeated ovarian stimulation failure/ fallopian tube blockage/ male factor) and ready for the 1st/ 2nd cycle of ivf; 6. cooperative to follow-ups and capable of reporting severe adverse event (sae); 7. completed informed consent. exclusion criteria: 1. unilateral ovary resection; 2. abnormal uterus cavity (congenital, chronic endometrium inflammation, polyps, adhesion, fibroids, etc); 3. chromosomal abnormality (either maternal or paternal); 4. recurrent abortion or recurrent failure of embryo transfer; 5. metformin allergy/ intolerance; 6. other serious or uncontrolled diseases (e.g. kidney insufficiency, infection, controlled hypertension, heart disease, etc); 7. preimplantation genetic testing; 8. other condition that may impact the results

Keywords: pcos glucose metabolism disorder ivf icsi time-restricted eating
effects of an adolescent physical activity promotion model on physical activity in obese chinese children.

Conditions: Obesity Prevention

Summary: the purpose of this study was to evaluate the effectiveness of an intervention program based on the youth physical activity promotion model (ypap) in increasing physical activity levels among overweight and obese children in china.

this observational study aims to understand the impact of a ypap-based intervention on the psychosocial factors and physical activity of overweight and obese children aged 12-15 in china. the intervention consists of three key components: 1) the intervention group received an 8-week intervention program aimed at gradually increasing their physical activity levels. the intervention program included the following components: 1) 1-2 sessions of moderate-intensity physical activity per week, each lasting 45 minutes, with activities provided by physical activity experts; 2) one health education lecture every two weeks, each lasting 60 minutes; and 3) one family physical activity session per week, each lasting 30 minutes at a lower intensity. at the end of the intervention period, relevant questionnaires were used for measurement.

Eligibility criteria:
inclusion criteria: * chinese children * aged between 12 and 15 years * able to complete questionnaires before and after the intervention * children who meet the standards for overweight and obesity among chinese school-age children exclusion criteria: * children with serious health issues (e.g., heart disease, respiratory diseases, severe musculoskeletal disorders) or those advised by a doctor not to participate in physical activities. * children currently involved in other intervention programs that affect physical activity or weight. * children without written consent from their parents or guardians. * children on long-term medication that might affect physical activity or weight (as determined by parents and teachers).

Keywords: overweight and obese children physical activity